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publicly funded organizations, and the former 
is an intergovernmental organization formed by 
a collection of mostly European member and 
associate member states.
Since the launch of the EGA, researchers 
from around the world have deposited and 
accessed data from over 700 of its studies of 
various types (Fig. 1 and Table 1). These studies 
vary from large-scale array-based genotyping 
experiments on thousands of samples in case-
control1,10 or population-based11,12 studies to 
sequencing-based studies designed to under-
stand changes in the genome, transcriptome or 
epigenome in both normal tissue13 and vari-
ous diseases such as cancer14–16. As a result, the 
EGA has grown from about 50 TB to 1,700 TB 
during the last 4 years.
Since 2011, the bulk of EGA submissions 
have transitioned from array-based geno-
typing to next-generation sequencing stud-
ies. Summary-level genetic information is 
also accepted if such data cannot be publicly 
released. Phenotype data are currently most 
often provided at the level of the data set rather 
than the individual; for example, a group of 
samples may be reported to have the same dis-
ease phenotype. However, submission of indi-
vidual-level, detailed phenotypes is increasing 
in frequency and is encouraged.
The technical ability to identify regions of the 
human genome that harbor variants influencing 
disease risk is one of the most important recent 
advances in genomics. Many studies use large 
disease cohorts, including the Wellcome Trust 
Case Control Consortium1 and the UK10K 
project. At the same time, the International 
Cancer Genome Consortium (ICGC) is gen-
erating the complete genomes of matching 
tumor and normal samples for a number of 
cancers in an effort to understand the genom-
ics of the disease. Published genetic variants are 
collated in fully public resources such as the 
National Human Genome Research Institute 
(NHGRI) Catalog of Published Genome-Wide 
Association Studies2 or Ensembl3. In addition 
to public variants, individual-level genetic and 
phenotypic data or summary statistics from the 
research projects are often required for replica-
tion4, meta-analysis5 and many other secondary 
uses, such as methods development6 or use as 
control samples7. However, these data must be 
processed, archived and transferred in a manner 
that respects the consent agreements signed by 
the study subjects8. This often means that data 
can only be provided to bona fide researchers 
and used for specific research aims9.
The existing public data archives that provide 
unrestricted access to data are incompatible 
with these requirements, and the EGA was thus 
launched in 2008 by the European Molecular 
Biology Laboratory’s European Bioinformatics 
Institute (EMBL-EBI) to support the voluntary 
archiving and dissemination of data requiring 
secure storage and distribution only to autho-
rized users. Recently, the EGA has expanded 
from an exclusively EMBL-EBI project to a 
collaboration with the Centre for Genome 
Regulation (CRG) in Barcelona, Spain, in what 
may be a first step toward a larger distributed 
network of data archiving and dissemination 
services. Both EMBL-EBI and the CRG are 
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data sets as a permanent part of the scientific 
record.
Biomolecular databases and archives 
are distributed worldwide with significant 
 concentrations at dedicated institutes, including 
NCBI and EMBL-EBI. Within this landscape, 
the EGA serves as a secure, authorized-access 
mechanism for data types that, if consented for 
fully open release, could otherwise have been 
deposited in the EMBL-EBI resources tailored 
to store DNA, RNA, protein or sample data20–22. 
In some cases, the EGA stores sample-level raw 
data files and detailed phenotype information, 
whereas aggregated results, such as disease-
associated variants, or other non-sensitive data 
are stored in the public archives with data set 
linking to enable discovery.
The EGA security policy includes the devel-
opment of a safe computing facility and a com-
prehensive suite of protocols for information 
management.
Access to data
The EGA has a distributed access-granting 
policy in which data access decisions are made 
by the nominated DAC for a given submission 
and not by the EGA. The DAC may consist of 
a dedicated committee formed by the funding 
or governmental organization that approved 
and monitored the initial study, an institutional 
committee or an individual primary investigator. 
Regardless of the scope or composition of the 
DAC, the EGA only provides services for stud-
ies when access decisions are made exclusively 
on the basis of scientific and ethical criteria in 
compliance with the original informed consent 
agreements. The EGA will withdraw service if 
data access is being denied selectively because of 
scientific competitiveness or other reasons not 
based on the original informed consent.
In a typical case, users wishing to access a spe-
cific data set apply directly to the corresponding 
DAC (Fig. 2), following contact instructions on 
the EGA website. Assuming approval, a Data 
Access Agreement (DAA) is made directly 
between the prospective user and the DAC, and 
it dictates data management policies, security 
arrangements and other potential limitations 
on data use. For example, some data may not be 
used for commercial purposes and users may 
be subject to a temporary publication embargo 
for projects participating in prepublication data 
release. In accordance with accepted practice, 
the EGA provides data access at the level of 
granularity that is appropriate for the submitted 
study. As an example, in a case-control study, the 
user may separately request to access individual-
level data only for the control data set.
Once approved for access, a user will be issued 
an EGA account, which is subject to a num-
ber of conditions, including that the account 
In this report, we describe the roles and poli-
cies of the EGA, provide information on how 
access decisions are made, outline the methods 
for data submission and dissemination, and 
describe the EGA system infrastructure. The 
EGA has similarities and differences with the 
database of Genotypes and Phenotypes (dbGaP) 
provided by NCBI17; where appropriate, we 
describe the features and procedures that dis-
tinguish these two databases.
Roles and policies of the EGA
The role of the EGA is to promote the distri-
bution and sharing of biomolecular and phe-
notypic data collected from human subjects 
who have consented to them being shared for 
research uses—but not for full, open public 
release—by providing a system for the secure 
archiving and dissemination of such data. 
Submitters are required to certify that the data 
they have deposited in the EGA have been pro-
duced and made available in a manner that is 
consistent with the original consent agreements, 
national laws and applicable regulations. Data 
sets submitted to the EGA are further required 
to be made accessible in a timely fashion to all 
bona fide researchers whose use of the data is 
consistent with the original consent agreements. 
As described below, the EGA brokers data access 
on behalf of the submitting organization and 
provides data management and distribution 
services for users of the database. Any security 
breach or data misuse by users is immediately 
reported to the relevant Data Access Committee 
(DAC) upon becoming known to the EGA, fol-
lowing a standard operating procedure.
The EGA supports prepublication data 
release in accordance with the Toronto agree-
ment for community resource projects18 and 
for other research organizations and funding 
agencies that require or encourage data release. 
For example, the data from the UK10K project 
are made available to authorized users as regu-
lar data updates during the project. In addi-
tion, the ICGC uses EGA to provide access to 
the raw sequence data and other appropriate 
data generated by many of the international 
partner projects19. The EGA also archives and 
distributes a wide range of data sets in support 
of scientific publications, providing published 
Figure 1  Breakdown of EGA studies by disease topic as of 2014. The majority (57%) of EGA studies 
investigate cancer of various types. EGA experimental data describe the methodology employed 
for each study, which is represented by the different colors. Exome sequencing (38%) is the most 
common methodology, followed by whole-genome sequencing (29%), array-based technologies 
(20%), transcriptomics (9%) and epigenomics (3%). As one might expect, array-based experiments 
are typically from older studies, whereas both transcriptomic and epigenomic investigations are more 
recent. A complete list of the meta-data collated to create this graph is provided on the EGA website. 
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Table 1  EGA users are distributed throughout the world as of May 2015
Geographical location Number of submitters Archived data (TB) Number of authorized data users
North and South America 53 341 1,995
Europe 137 1,204 2,608
Asia 38 130 556
Oceania 7 110 246
Africa 0 0 5
Total 235 1,785 6,601a
aThe total number of authorized users includes 1,191 from commercial organizations, which have not been separated geo-
graphically.
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controlled-access data stored in the EGA is pro-
vided through the data set page. Each data set 
includes publicly available information about 
the technology used to assay the samples and 
guidelines describing how to apply for data 
access. Once access has been granted and users 
have logged into the secure EGA website, the 
page will show all the associated manufacturer 
raw data files, processed information such as 
variants or genotypes, or any associated study 
summary data. Logging into an EGA account 
facilitates data requests from the archive and 
allows users to track their current requests 
within the system.
All data are encrypted for dissemination and 
made available to each authorized user through 
FTP as well as fast Internet transfer protocols 
such as Aspera and UDT. Data transmission 
methods for submission and dissemination 
have evolved as data volumes have increased and 
now include a custom Java client making use of 
the UDT protocol and performing automatic 
MD5-checksum validation and encryption. This 
automation has increased user-friendliness and 
reduced error.
Data submission
Complete up-to-date information about sub-
mitting data to the EGA is available from its 
websites. Briefly, submitters first request a 
private submission account from the EGA to 
information not be shared. EGA accounts can 
be updated with additional access rights upon 
each successful application. To ensure that the 
DAA remains valid, the EGA requires DAC 
authorization for changes to user details, such as 
institutional affiliation. The EGA offers support 
and online tools for the DACs to manage the 
access rights for their data sets directly within 
the system.
The policy of distributed access-granting is 
the most important distinguishing feature of the 
EGA in comparison to dbGaP. Authorization 
decisions for dbGaP’s data sets are made by the 
US National Institutes of Health (NIH) institute 
that sponsored the study in question. In the 
United States, the NIH serves as both a fund-
ing and policy-making agency and, through 
the NCBI, a mechanism for data distribution. 
This allows the NIH to specify dbGaP as a 
required (although non-exclusive) data distri-
bution channel for specific studies. In contrast, 
the rest of the world has a diversity of funding 
agencies and national regulations, and these are 
very often compatible with the distributed data 
access policy of the EGA for data archiving and 
distribution. Indeed, this distributed model is 
an especially good fit for the European research 
structures that provide support to the EGA.
The EGA and dbGaP share meta-data to 
improve the discoverability of data deposited 
in either repository. This sharing of publicly 
available information such as study name and 
publication information enables researchers to 
search for data sets and find the relevant starting 
point for the access approval process, regardless 
of whether the data are in the EGA or dbGaP. 
Data are only disseminated from the archive 
that accepted the original submission, as actual 
data files are not exchanged between the EGA 
and dbGaP.
The EGA websites
Users can access the full EGA service from its 
instance at either EMBL-EBI or the CRG. Both 
current EGA websites are arranged around the 
study concept. A study is typically an experimen-
tal investigation of a particular phenomenon, for 
example, a genome-wide association study or a 
matched tumor-normal cancer genome project. 
The EGA study page describes how the study 
was conducted and all the associated data sets. 
The page also includes links to other relevant 
data resources at the EMBL-EBI or NCBI, the 
primary publication when available and the data 
provider. Studies, data sets, DACs and data pro-
viders are assigned stable identifiers that should 
be referred to in the publication and are used 
to link together information within the EGA. 
These identifiers provide direct access to the rel-
evant EGA webpage through the central EMBL-
EBI search engine and serve as stable URLs.
The primary point of entry for accessing the 
Figure 2  The EGA distributed data access model. The EGA refers applicants to appropriate DACs on the website. Each DAC grants access to its data 
independently. The EGA will create a personal account for each approved applicant listed on the application. The account holds all approved data access 
permissions and allows account holders to request services from the EGA team, such as downloading of encrypted files from the archive or support for any 
technical or data content–related questions. The data downloaded from the EGA website are provided under a DAA, which is a legal agreement between each 
approved user and the data-governing DAC.
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access the range of tools available for file and 
meta-data upload. It is recommended that all 
primary data files be uploaded using the secure 
EGA application that automatically provides 
data encryption and transfer integrity checks. 
Meta-level information about a study should 
be submitted using either the Webin online 
tool22 for experiments using next-generation 
sequencing technology or an EGA-provided 
spreadsheet-based meta-data submission 
template for other assay types. It is also pos-
sible for submitters to connect local informa-
tion management systems directly to the EGA 
for automatic submission support. The EGA 
submission guidelines provide detailed infor-
mation about each stage (Table 2). To ensure 
that all possible submitters can be served by the 
EGA, encrypted data will also be accepted on 
hard drives if data size or submitter bandwidth 
necessitates this.
Once the submission has been completed, 
the EGA confirms the integrity of each sub-
mitted file, transfers the data into a secure 
computing area, and decrypts and uploads it 
into archival databases. The EGA staff work 
directly with the submitter to make sure that 
the data are correctly uploaded into the sys-
tem, pass quality checks and are accurately 
represented on the website. While data are 
being collected and analyzed, all uploaded 
files and the website may be made visible to 
research collaborators, referees for manu-
scripts under review provided they are will-
ing to state their identity and make an access 
application to the appropriate DAC, or any 
other approved users. The EGA supports a 
‘hold until publication’ (HUP) status for 6–12 
months to enable a study to be submitted and 
verified but kept private until it is released 
simultaneously with a journal publication. 
There is no defined maximum time that a data 
set can remain in HUP status, but extensions 
beyond 1 year require justification. Although 
all published data are made available as soon 
as possible, actual initiation of data dissemi-
nation from the EGA requires authorization 
from the submitting organization.
Future directions
The recent expansion of the EGA to an EMBL-
EBI and CRG collaboration will help support 
major new EGA data sets, including genomic 
data from the Genome of the Netherlands23 
and Deciphering Developmental Disorders24 
projects, epigenetic and functional data from 
the Blueprint25 and HipSci consortia, and data 
relevant to the genetic basis of rare disease from 
the UK BRIDGE Project.
The EGA is also working on several new 
added-value services that will increase the 
usability of the submitted data. For example, 
submitted sample phenotypes will be described 
using ontology-based terms to facilitate better 
search functionality and assist users looking to 
merge data across studies. Links are being estab-
lished with literature databases such as Europe 
PubMed Central to more closely track second-
ary publications based on data from the EGA. 
The EGA will also provide a variant calling and 
imputation service for limited sets of data sub-
mitted to the database. Finally, with the support 
of the Barcelona Supercomputing Center (BSC) 
and user-facing EMBL-EBI computational 
resources, the EGA is exploring cloud-based 
data analysis options.
URLs. EGA website, http://www.ebi.ac.uk/
ega/ or http://ega.crg.eu/; UK10K Project, 
http://www.uk10k.org/; US NIH Data 
Sharing Policies, http://www.nlm.nih.gov/
NIHbmic/nih_data_sharing_policies.html; 
HipSci Project, http://www.hipsci.org/; UK 
BRIDGE Project, https://bridgestudy.med-
schl.cam.ac.uk/; Europe PubMed Central, 
http:// europepmc.org/.
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Table 2  Further information available from the EGA website
Guidelines Description Example web addressa
Introduction to EGA Documents related to EGA processes, 
stable identifiers and Frequently Asked 
Questions
https://ega.crg.eu/about/introduction 
Tutorial videos Video library for EGA account holders, 
data submitters or DAC members
http://www.ebi.ac.uk/ega/about/videos
Submissions to EGA Submission manual for all experiment 
types and Frequently Asked Questions
https://ega.crg.eu/submission 
DACs Documentation explaining how to estab-
lish and manage a DAC effectively
http://www.ebi.ac.uk/ega/submission/data_
access_committee 
EGA tools Collection of EGA tools for data down-
load or the submission process
https://ega.crg.eu/submission/tools 
EGA security EGA security policies https://www.ebi.ac.uk/ega/about/security 
aAll EGA policies are available from both the CRG website and the EMBL-EBI website by using either http://ega.crg.eu or http://
www.ebi.ac.uk/ega, respectively, the listed URL.
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